CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

Article Date

This article is featured on another website.

Go to article
June 25, 2024

Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies

Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]

June 25, 2024

Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies

Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]